Summary The polymerase chain reaction has been used to determine the presence of human papillomavirus (HPV) 16 and HPV 18 DNA sequences in archival histological material removed from a cohort of untreated women with cervical epithelial abnormalities. The detection of HPV 16 or 18 DNA sequences in the initial biopsy specimen was associated with a significantly increased risk of subsequent disease progression.
Over the last 12 years a stream of imaginative and resourceful laboratory-based research has established an impressive set of oncogenic credentials for human papillomavirus (HPV) . Two large population-based case-control studies have provided further support for its aetiological role in cervical neoplasia (Reeves et al., 1989; Munoz et al., 1992) and we now await the outcome of cohort studies in which longitudinal observations are made on subjects whose exposure status has been defined before the onset of disease. Such studies are under way but it will be some time before they are reported. An alternative strategy is to recruit a cohort of subjects who are likely to be at greater risk of developing cervical intraepithelial neoplasm (CIN) III and to determine the risk of progression in this cohort according to baseline HPV status. The aim of this study was to describe the association between the finding of HPV DNA sequences in the initial biopsies taken from a cohort of untreated patients with epithelial abnormalities of the cervix and the risk of subsequent progression of disease.
Patients and methods
A randomised control trial undertaken some years ago provided a cohort of untreated patients with cervical epithelial abnormalities. The details of this trial have been outlined elsewhere (Kaplan and Meier, 1958 (Machin and Gardner, 1988 (Figure 2 ). 
The same techniques must be used to establish follow-up and baseline disease status. It is not, for example, acceptable to define baseline disease status on the results of colposcopically directed punch biopsy and outcome on the results of a loop biopsy or cone biopsy. The use of the latter techniques allow for the removal of substantially greater volumes of tissue that provide for a more precise topographical description of the severity of the lesion.
There is a further difficulty in deciding what change in disease severity constitutes evidence of disease progression. Intuitively, the discovery of a CIN III lesion in a patient found to have CIN I at baseline provides more persuasive evidence of progression than when a CIN II lesion is discovered after the initial diagnosis of CIN I. Alternatively, both examples could be construed as evidence of progression from a 'low-grade' (HPV/CIN I) to a 'highgrade' lesion (CIN II/III). It might also be argued that changes in disease status over a short period of time are more likely to reflect misclassification following sampling error rather than true progression. Unfortunately, this requires us to make prior assumptions about the tempo of disease progression. These difficulties would be reduced, but not abolished, if CIN III alone was used as the study end point.
When this study was initiated ethical considerations dictated that women be treated at the time of histological confirmation of any disease progression. This was almost certainly unnecessary, as some cases might still have undergone spontaneous regression of epithelial abnormality. Nevertheless, sufficient women in this series have progressed to CIN III without any detectable intermediate stage to reveal a significant association between baseline HPV status and progression to CIN III.
All of the above caveats relating to the definition of baseline disease status also apply to the definition of baseline virological status, which will be influenced by the detection system used, the material provided for analysis and the accuracy of the sampling technique.
In this study we have only considered the prognostic importance of finding HPV 16 and 18 DNA sequences. We did not test for the presence of HPV 6/11 sequences because there was no a priori reason to believe these types were associated with an increased risk of disease progression. A high prevalence of other 'high-risk ' HPV types (31, 33, 35, 39, 45 , 51 or 52) have been reported in some North American series but surprisingly infrequently in this country (Cuzick et al., 1992; Schiffman et al., 1993) . This may, of course, merely reflect the assiduousness with which they have been sought. If we had tested for the presence of other 'high-risk' HPV DNA types, this might have accentuated the difference between the progression curves.
Given these uncertainties, how robust are the conclusions that can be drawn from any analysis of risk factors for disease progression? It is clear that misclassification of virological status and disease status at baseline and during follow-up will have occurred. It is important to decide if this misclassification is likely to be random or systematic. Random misclassification will merely reduce differences between groups and attenuate measures of association. Systematic misclassification is more serious. If, for example, prior knowledge of virological status were to influence baseline or more importantly follow-up disease status, as a result of more intensive follow-up of HPV-positive patients, then spurious conclusions might be drawn. However, if virological status, baseline disease and follow-up status are independently defined, then these errors are likely to be random and as such will only underestimate the true risk of progression associated with HPV status. In this study the technological developments necessary to determine virological status only became available some years after the clinical trial had been completed, and both pathologist and clinician were therefore blind to the baseline HPV status of the cases.
The next major concern relates to the possibility of confounding. The association of HPV status with progression may be confounded if HPV infection is also associated with another factor that is itself a risk factor for progression. Risk of disease progression may be associated with baseline disease status but this study revealed a consistent association with HPV status for each level of baseline abnormality. Size of lesion has also been described as a risk factor for disease progression but there is no evidence linking HPV status and size. One other study has shown that the risk of disease progression is associated with the finding of other sexually transmitted agents including HPV but this analysis confirmed HPV status as an independent risk factor (Koutsky et al., 1992) .
There is another more serious reservation that applies to all natural history studies that use CIN III as an end point. Although the presence of HPV 16/18 infection may accelerate progression to CIN III, not all cases of CIN III will progress to invasive cancer . As we cannot yet distinguish those cases which will progress it might be unwise to infer from these data that HPV infection results in the inexorable progression of all CIN lesions to invasive cancer.
